383 related articles for article (PubMed ID: 31814726)
1. Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm.
Wang Y; Patel A; Douglas RS
Ther Clin Risk Manag; 2019; 15():1305-1318. PubMed ID: 31814726
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
[TBL] [Abstract][Full Text] [Related]
3. A New Era in the Treatment of Thyroid Eye Disease.
Patel A; Yang H; Douglas RS
Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
[TBL] [Abstract][Full Text] [Related]
4. Teprotumumab: A Review in Thyroid Eye Disease.
Nie T; Lamb YN
Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
[TBL] [Abstract][Full Text] [Related]
5. Updates on the understanding and management of thyroid eye disease.
Men CJ; Kossler AL; Wester ST
Ther Adv Ophthalmol; 2021; 13():25158414211027760. PubMed ID: 34263138
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab for the treatment of thyroid eye disease.
Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
8. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
Ugradar S; Kossler AL; Douglas R; Cockerham K
J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
Thyroid; 2024 Jun; ():. PubMed ID: 38824618
[No Abstract] [Full Text] [Related]
10. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
[TBL] [Abstract][Full Text] [Related]
11. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
[No Abstract] [Full Text] [Related]
12. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
[TBL] [Abstract][Full Text] [Related]
13. Teprotumumab for the treatment of Thyroid eye disease.
Ugradar S; Malkhasyan E; Douglas RS
Endocr Rev; 2024 Jun; ():. PubMed ID: 38838219
[TBL] [Abstract][Full Text] [Related]
14. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.
Jain AP; Gellada N; Ugradar S; Kumar A; Kahaly G; Douglas R
Br J Ophthalmol; 2022 Feb; 106(2):165-171. PubMed ID: 33172865
[TBL] [Abstract][Full Text] [Related]
15. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.
Cockerham KP; Padnick-Silver L; Stuertz N; Francis-Sedlak M; Holt RJ
Ophthalmol Ther; 2021 Dec; 10(4):975-987. PubMed ID: 34478126
[TBL] [Abstract][Full Text] [Related]
16. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
Smith TJ
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
[TBL] [Abstract][Full Text] [Related]
17. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
18. Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report.
Singh G; Taylor B; Michalek S
Cureus; 2023 Nov; 15(11):e48861. PubMed ID: 38111423
[TBL] [Abstract][Full Text] [Related]
19. Future Projections in Thyroid Eye Disease.
Barbesino G; Salvi M; Freitag SK
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
[TBL] [Abstract][Full Text] [Related]
20. Improvement of asymmetric thyroid eye disease with teprotumumab.
Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
